Denintuzumab

Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia[1].

[1] Farhadfar N, et al. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. Leuk Res. 2016 Oct;49:13-21. DOI:10.1016/j.leukres.2016.07.009